pCR, which is defined as the absence of invasive cancer in the breast and lymph nodes after treatment, can be measured within weeks of starting a drug. Thus, it can provide a very early indicator ...

Neoadjuvant therapy that resulted in pathologic complete response (pCR) reduced the risk of breast cancer recurrence by 80%, pooled data from a phase II clinical trial platform showed.

Across various breast cancer receptor signatures, pCR rates ranged from 36% to 53% with the combination of paclitaxel, the PD-1 inhibitor cemiplimab (Libtayo), and the investigational LAG-3 ...

Over the past few years, scientists from a variety of disciplines have applied digital PCR (dPCR) as a potentially useful tool for breast cancer screening, measuring latent HIV reservoirs in ...

Pathologic complete response (pCR) is not a reliable surrogate endpoint in trials evaluating neoadjuvant therapies for early breast cancer, according to a critical analysis of the literature. A ...

Therefore, in the case of pCR, the challenge is to distinguish between the few high-risk patients needing treatment intensification and those at risk of overtreatment, because of their favorable ...

ECOG-ACRIN presented the CompassHER2 trial’s pCR rates after 12 weeks of neoadjuvant THP in early-stage HER2+ breast cancer patients, identifying predictors of treatment benefit.

Background: In BC, pCR is associated with substantial survival benefit. Hence, escalated neoadjuvant treatments (NATs) are being increasingly employed to improve pCR rates, warranting biomarkers for ...

The Asia-Pacific molecular oncology diagnostics market, valued at $513.6 million in 2024, is projected to surge to $1.54 ...